GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » EV-to-EBITDA

Accelerate Diagnostics (STU:1A80) EV-to-EBITDA : -0.97 (As of May. 17, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Accelerate Diagnostics's enterprise value is €41.00 Mil. Accelerate Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-42.43 Mil. Therefore, Accelerate Diagnostics's EV-to-EBITDA for today is -0.97.

The historical rank and industry rank for Accelerate Diagnostics's EV-to-EBITDA or its related term are showing as below:

STU:1A80' s EV-to-EBITDA Range Over the Past 10 Years
Min: -67.89   Med: -14.02   Max: -0.8
Current: -0.91

During the past 13 years, the highest EV-to-EBITDA of Accelerate Diagnostics was -0.80. The lowest was -67.89. And the median was -14.02.

STU:1A80's EV-to-EBITDA is ranked worse than
100% of 488 companies
in the Medical Devices & Instruments industry
Industry Median: 16.14 vs STU:1A80: -0.91

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), Accelerate Diagnostics's stock price is €0.83. Accelerate Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-4.238. Therefore, Accelerate Diagnostics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Accelerate Diagnostics EV-to-EBITDA Historical Data

The historical data trend for Accelerate Diagnostics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics EV-to-EBITDA Chart

Accelerate Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.06 -8.69 -6.72 -1.81 -1.67

Accelerate Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.98 -1.72 -1.87 -1.67 -0.95

Competitive Comparison of Accelerate Diagnostics's EV-to-EBITDA

For the Medical Devices subindustry, Accelerate Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's EV-to-EBITDA falls into.



Accelerate Diagnostics EV-to-EBITDA Calculation

Accelerate Diagnostics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=41.004/-42.432
=-0.97

Accelerate Diagnostics's current Enterprise Value is €41.00 Mil.
Accelerate Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-42.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerate Diagnostics  (STU:1A80) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Accelerate Diagnostics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.83/-4.238
=At Loss

Accelerate Diagnostics's share price for today is €0.83.
Accelerate Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.238.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Accelerate Diagnostics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerate Diagnostics (STU:1A80) Business Description

Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Accelerate Diagnostics (STU:1A80) Headlines

No Headlines